Michael Dellinger, Ph.D., received his B.S. and Ph.D. degrees in Molecular and Cellular Biology from the University of Arizona. Dr. Dellinger’s training in lymphology began while he was a graduate student in the laboratories of Drs. Marlys Witte and Robert Erickson. As a graduate student, he investigated the molecular mechanisms controlling the development of the lymphatic vasculature and the genetic underpinnings of human diseases caused by errors in this essential process.

After completing his graduate work, he joined Rolf Brekken’s laboratory at UT Southwestern Medical Center. In Dr. Brekken’s laboratory he studied the role of the VEGF-A/VEGFR2 pathway in promoting developmental and tumor lymphangiogenesis.

In 2014, Dr. Dellinger became an Assistant Professor in the Department of Surgery at UT Southwestern Medical Center. The research in his laboratory is focused on developing animal models of lymphatic anomalies and using these models to identify novel therapies to treat patients. Additionally, his laboratory studies the molecular mechanisms controlling developmental and tumor lymphangiogenesis.  


University of Arizona (2002), Molecular & Cell Biology
Graduate School
University of Arizona (2008), Molecular & Cell Biology

Research Interest

  • Development of the Lymphatic Vasculature
  • Gorham-Stout disease
  • Lymphangiogenesis
  • Lymphangiomatosis/Generalized Lymphatic Anomaly
  • Lymphatic Malformation
  • Lymphedema
  • Tumor Lymphangiogenesis


Featured Publications LegendFeatured Publications

Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia.
Witte MH, Dellinger MT, Papendieck CM, Boccardo F Clin. Exp. Metastasis 2012 Oct 29 7 707-27
Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax.
Kanady JD, Dellinger MT, Munger SJ, Witte MH, Simon AM Dev. Biol. 2011 Jun 354 2 253-66
Lymphangiogenesis and hemangiogenesis: potential targets for therapy.
Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, Gershenwald JE J Surg Oncol 2011 May 103 6 489-500
Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.
Dellinger MT, Brekken RA PLoS ONE 2011 6 12 e28947
Lymphedema-distichiasis syndrome without FOXC2 mutation: evidence for chromosome 16 duplication upstream of FOXC2.
Witte MH, Erickson RP, Khalil M, Dellinger M, Bernas M, Grogan T, Nitta H, Feng J, Duggan D, Witte CL Lymphology 2009 Dec 42 4 152-60
Novel FOXC2 missense mutation identified in patient with lymphedema-distichiasis syndrome and review.
Dellinger MT, Thome K, Bernas MJ, Erickson RP, Witte MH Lymphology 2008 Sep 41 3 98-102

Honors & Awards

  • NAVBO Outstanding Poster Award
  • UTSW Department of Surgery Basic Science Award
  • UTSW Department of Surgery Basic Science Award
  • Lymphatic Research Foundation Award
  • International Society of Lymphology Presidential Prize
  • Lymphatic Research Foundation Award
  • International Society of Lymphology Presidential Prize

Professional Associations/Affiliations

  • North American Vascular Biology Association (2012)
  • International Society of Lymphology (2005)